The Importance of Alliance between Hematologists and Dentists: A Retrospective Study on the Development of Bisphosphonates Osteonecrosis of the Jaws (Bronj) in Multiple Myeloma Patients

被引:5
|
作者
Bacci, Christian [1 ]
Cerrato, Alessia [1 ]
Dotto, Virginia [1 ]
Zambello, Renato [2 ]
Barila, Gregorio [2 ]
Lico, Albana [2 ]
Semenzato, Gianpietro [2 ]
Stellini, Edoardo [1 ]
Zanette, Gastone [1 ]
机构
[1] Univ Padua, Clin Dent Dept Neurosci, Via Giustiniani 1, I-35128 Padua, Italy
[2] Univ Padua, Dept Med, Hematol & Clin Immunol Sect, I-35128 Padua, Italy
关键词
MRONJ; BRONJ; ONJ; osteonecrosis; myeloma; bisphosphonates; ZOLEDRONIC ACID; RECOMMENDATIONS; EPIDEMIOLOGY; DIAGNOSIS; CANCER; ONJ;
D O I
10.3390/dj9020011
中图分类号
R78 [口腔科学];
学科分类号
1003 ;
摘要
(1) Background: Multiple myeloma is a rare cancer that primarily affects the bone marrow. Osteoclasts are responsible for increased bone resorption and, therefore, bone destruction. Bisphosphonates are a class of drugs that can slow down bone resorption by reducing the number and action of osteoclasts. Intravenous injections of bisphosphonates (generally Zoledronic Acid) are administered to patients affected by Multiple Myeloma, but BRONJ is described as a serious side effect. This 5-year retrospective study aims to evaluate the efficacy of appropriate dental treatment protocols prior to initiating bisphosphonate therapy to prevent the development of BRONJ. (2) Methods: A total of 99 patients with symptomatic multiple myeloma were involved in this study (41-90 years, mean age 65 years, standard deviation 5 years). The data relating to the visits were tracked using a specific server and consulting the clinical reports. The AAOMS (American Association of Oral and Maxillofacial Surgeons) position was applied for both diagnosis and treatment. A total of 79 patients were examined before the administration of bisphosphonates (group A) and 20 after (group B). (3) Results: The entire sample required dental treatment: 23.2% underwent restorative therapy, 8% endodontic treatments, 44.4% tooth extractions. Periodontal disease was present in 41.4% of the patients. No osteonecrosis was observed in the first group, whereas BRONJ was found in five patients of the second one (25%) and two patients (10%) showed osteosclerotic areas under investigation [OR 0.026 (CI 0.0027 to 0.2454)]. (4) Conclusions: In the literature, there are no precise data about the prevalence of BRONJ. Despite the limitation of the present study, we point out that dental treatment before the treatment with intravenous bisphosphonates can help in reducing the incidence of BRONJ and good dental status is necessary for BRONJ prevention.
引用
收藏
页数:7
相关论文
共 8 条
  • [1] Bisphosphonates Induce Apoptosis of Circulating Endothelial Cells in Multiple Myeloma Patients and in Subjects with Bisphosphonate-Induced Osteonecrosis of the Jaws
    Allegra, Alessandro
    Alonci, Andrea
    Penna, Giuseppa
    Granata, Angela
    Siniscalchi, Enrico Nastro
    Oteri, Giacomo
    Loddo, Saverio
    Teti, Diana
    Ciccu, Domenico
    De Ponte, Francesco Saverio
    Musolino, Caterina
    ACTA HAEMATOLOGICA, 2010, 124 (02) : 79 - 85
  • [2] Role of intravenous dosage regimens of bisphosphonates in relation to other aetiological factors in the development of osteonecrosis of the jaws in patients with myeloma
    Jarnbring, Fredrik
    Kashani, Ali
    Bjork, Andreas
    Hoffman, Tobias
    Krawiec, Kamilla
    Ljungman, Per
    Lund, Bodil
    BRITISH JOURNAL OF ORAL & MAXILLOFACIAL SURGERY, 2015, 53 (10): : 1007 - 1011
  • [3] Bisphosphonate-induced osteonecrosis of the jaws: Prospective study of 80 patients with multiple myeloma and other malignancies
    Boonyapakorn, Thacharot
    Schirmer, Ingrid
    Reichart, Peter A.
    Sturm, Isrid
    Massenkeil, Gero
    ORAL ONCOLOGY, 2008, 44 (09) : 857 - 869
  • [4] Evolution of bisphosphonate-related osteonecrosis of the jaw in patients with multiple myeloma and Waldenstrom's macroglobulinemia: a retrospective multicentric study
    Andriani, A.
    Petrucci, M. T.
    Caravita, T.
    Montanaro, M.
    Villiva, N.
    Levi, A.
    Siniscalchi, A.
    Bongarzoni, V.
    Pisani, F.
    De Muro, M.
    Coppetelli, U.
    Avvisati, G.
    Zullo, A.
    Agrillo, A.
    Gaglioti, D.
    BLOOD CANCER JOURNAL, 2012, 2 : e62 - e62
  • [5] A retrospective study assessing the incidence, risk factors and comorbidities of pamidronate-related necrosis of the jaws in multiple myeloma patients
    Jadu, F.
    Lee, L.
    Pharoah, M.
    Reece, D.
    Wang, L.
    ANNALS OF ONCOLOGY, 2007, 18 (12) : 2015 - 2019
  • [6] Evolution of bisphosphonate-related osteonecrosis of the jaw in patients with multiple myeloma and Waldenstrom's macroglobulinemia: a retrospective multicentric study
    A Andriani
    M T Petrucci
    T Caravita
    M Montanaro
    N Villivà
    A Levi
    A Siniscalchi
    V Bongarzoni
    F Pisani
    M De Muro
    U Coppetelli
    G Avvisati
    A Zullo
    A Agrillo
    D Gaglioti
    Blood Cancer Journal, 2012, 2 : e62 - e62
  • [7] Bortezomib administration is a risk factor associated with the development of tumor lysis syndrome in male patients with multiple myeloma: a retrospective study
    Kondo, Masahiro
    Hotta, Yuji
    Yamauchi, Karen
    Sanagawa, Akimasa
    Komatsu, Hirokazu
    Iida, Shinsuke
    Kimura, Kazunori
    BMC CANCER, 2020, 20 (01)
  • [8] A retrospective cohort study of venous thromboembolism(VTE) in 1035 Japanese myeloma patients treated with thalidomide; lower incidence without statistically significant association between specific risk factors and development of VTE and effects of thromboprophylaxis with aspirin and warfarin
    Kato, Atsushi
    Takano, Hina
    Ichikawa, Ayako
    Koshino, Mayuko
    Igarashi, Aiko
    Hattori, Keiichiro
    Nagata, Kaoru
    THROMBOSIS RESEARCH, 2013, 131 (02) : 140 - 144